FDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish.
作者信息
Ahmed Syed Mukhtar, Shivnaraine Rabindra V, Wu Joseph C
机构信息
Stanford Cardiovascular Institute, Stanford, CA (S.M.A., J.C.W.).
Greenstone Biosciences, Palo Alto, CA (S.M.A., R.V.S.).
出版信息
Circulation. 2023 Jul 25;148(4):309-311. doi: 10.1161/CIRCULATIONAHA.123.065585. Epub 2023 Jul 24.
Abstract
摘要
相似文献
1
FDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish.《美国食品药品监督管理局现代化法案2.0》为计算生物学和培养皿中的临床试验铺平了道路。
Circulation. 2023 Jul 25;148(4):309-311. doi: 10.1161/CIRCULATIONAHA.123.065585. Epub 2023 Jul 24.
2
Next-Gen Therapeutics: Pioneering Drug Discovery with iPSCs, Genomics, AI, and Clinical Trials in a Dish.下一代疗法：利用诱导多能干细胞、基因组学、人工智能以及体外临床试验开拓药物研发。
Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):71-90. doi: 10.1146/annurev-pharmtox-022724-095035. Epub 2024 Dec 17.
3
FDA Modernization Act 2.0: An insight from nondeveloping country.《FDA 现代化法案 2.0：来自非发达国家的观察》。
Drug Dev Res. 2023 Dec;84(8):1572-1577. doi: 10.1002/ddr.22108. Epub 2023 Aug 17.
4
Clinical Trials in a Dish.盘中临床试验
Trends Pharmacol Sci. 2017 Jan;38(1):4-7. doi: 10.1016/j.tips.2016.10.009. Epub 2016 Nov 19.
5
Clinical Trial in a Dish for Space Radiation Countermeasure Discovery.在太空辐射对策发现的临床实验。
Life Sci Space Res (Amst). 2022 Nov;35:140-149. doi: 10.1016/j.lssr.2022.05.006. Epub 2022 May 27.
6
Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development.人类多能干细胞衍生模型作为药物发现与开发中缺失的环节
Pharmaceuticals (Basel). 2021 May 30;14(6):525. doi: 10.3390/ph14060525.
7
Pluripotent stem cells: the last 10 years.多能干细胞：过去十年
Regen Med. 2016 Dec;11(8):831-847. doi: 10.2217/rme-2016-0117. Epub 2016 Dec 2.
8
Realizing the promise of the US Food and Drug Administration Modernization Act.实现美国食品药品监督管理局现代化法案的承诺。
Clin Ther. 1998;20 Suppl C:C26-31. doi: 10.1016/s0149-2918(98)80005-2.
9
Human stem cell-derived oligodendrocytes: From humanized animal models to cell therapy in myelin diseases.人源干细胞来源的少突胶质细胞：从人源化动物模型到髓鞘疾病的细胞治疗。
Semin Cell Dev Biol. 2021 Aug;116:53-61. doi: 10.1016/j.semcdb.2020.09.011. Epub 2020 Oct 17.
10
Application of Computational Biology and Artificial Intelligence in Drug Design.计算生物学和人工智能在药物设计中的应用。
Int J Mol Sci. 2022 Nov 5;23(21):13568. doi: 10.3390/ijms232113568.
引用本文的文献
1
Optimal dosing of anti-cancer treatment under drug-induced plasticity.药物诱导可塑性下的抗癌治疗最佳剂量
NPJ Syst Biol Appl. 2025 Aug 25;11(1):98. doi: 10.1038/s41540-025-00571-5.
2
Response of human iPSC-cardiomyocytes to adrenergic drugs assessed by high-throughput pericellular oxygen measurements.通过高通量细胞周围氧气测量评估人诱导多能干细胞衍生心肌细胞对肾上腺素能药物的反应。
bioRxiv. 2025 Jul 3:2025.06.27.662066. doi: 10.1101/2025.06.27.662066.
3
Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective.用于精准医学的综合患者数字双胞胎和仿生双胞胎：一种观点
Semin Liver Dis. 2025 Jul 23. doi: 10.1055/a-2649-1560.
4
Pericellular oxygen dynamics in human cardiac fibroblasts and iPSC-cardiomyocytes in high-throughput plates: insights from experiments and modeling.高通量培养板中人类心脏成纤维细胞和诱导多能干细胞衍生心肌细胞的细胞周围氧动力学：实验与建模的见解
J Mol Cell Cardiol Plus. 2025 Jun 11;13:100464. doi: 10.1016/j.jmccpl.2025.100464. eCollection 2025 Sep.
5
Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting.用于癌症成像的正电子发射断层显像（PET）放射性示踪剂的翻译：美国国家癌症成像转化加速器（NCITA）共识会议的建议
BMC Med. 2025 Jan 23;23(1):37. doi: 10.1186/s12916-024-03831-z.
6
Gelatin methacryloyl biomaterials and strategies for trophoblast research.明胶甲基丙烯酰基生物材料及滋养层研究策略。
Placenta. 2024 Nov;157:67-75. doi: 10.1016/j.placenta.2024.09.016. Epub 2024 Sep 24.
7
Next-Gen Therapeutics: Pioneering Drug Discovery with iPSCs, Genomics, AI, and Clinical Trials in a Dish.下一代疗法：利用诱导多能干细胞、基因组学、人工智能以及体外临床试验开拓药物研发。
Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):71-90. doi: 10.1146/annurev-pharmtox-022724-095035. Epub 2024 Dec 17.
8
Clinical trials in-a-dish for cardiovascular medicine.在心血管医学中进行临床试验。
Eur Heart J. 2024 Oct 21;45(40):4275-4290. doi: 10.1093/eurheartj/ehae519.
9
In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment.从 3D hiPSC 衍生的心脏微组织的体外到体内外推，以及基于生理学的药代动力学建模，为下一代心律失常风险评估提供信息。
Toxicol Sci. 2024 Sep 1;201(1):145-157. doi: 10.1093/toxsci/kfae079.
10
The new era of cardiovascular research: revolutionizing cardiovascular research with 3D models in a dish.心血管研究的新时代：利用培养皿中的3D模型革新心血管研究。
Med Rev (2021). 2024 Feb 20;4(1):68-85. doi: 10.1515/mr-2023-0059. eCollection 2024 Feb.
本文引用的文献
1
2022 FDA approvals.2022年美国食品药品监督管理局的批准情况。
Nat Rev Drug Discov. 2023 Feb;22(2):83-88. doi: 10.1038/d41573-023-00001-3.
2
Challenges and opportunities for the next generation of cardiovascular tissue engineering.下一代心血管组织工程面临的挑战与机遇。
Nat Methods. 2022 Sep;19(9):1064-1071. doi: 10.1038/s41592-022-01591-3. Epub 2022 Sep 5.
3
Shifting machine learning for healthcare from development to deployment and from models to data.将医疗保健领域的机器学习从开发转移到部署，从模型转移到数据。
Nat Biomed Eng. 2022 Dec;6(12):1330-1345. doi: 10.1038/s41551-022-00898-y. Epub 2022 Jul 4.
4
Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy.使用诱导多能干细胞进行的体外临床试验表明，洛伐他汀可改善LMNA心肌病中的内皮功能障碍和细胞间相互作用。
Sci Transl Med. 2020 Jul 29;12(554). doi: 10.1126/scitranslmed.aax9276.
5
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.酏剂、稀释剂与1938年《联邦食品、药品和化妆品法案》的通过
Ann Intern Med. 1995 Mar 15;122(6):456-61. doi: 10.7326/0003-4819-122-6-199503150-00009.
Zotero 插件